Celgene
NASDAQ: CELG
$108.24
+$0.00 (+0.0%)
Closing Price on November 22, 2019
CELG Articles
The short interest data are out for the January 30 settlement date. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
Published:
Here are the five biotech stocks that are loved the most by portfolio managers, according to Cowen analysts.
Published:
Celgene Corp. (NASDAQ: CELG) reported better-than-expected fourth-quarter earnings on Thursday morning.
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. For the majority of the selected stocks, short interest is down.
Published:
24/7 Wall St. has reviewed the short interest in the top biotech companies, without focusing on speculative companies.
Published:
Celgene Corp. provided a preliminary look at its financials for 2014 but also gave its financial outlook for 2015 and far beyond at the Annual J.P. Morgan Healthcare Conference.
Published:
ThinkstockLooking back at 2014, biotechs had a phenomenal year, and this looks to continue into 2015. The NYSE Arca Biotech index was up over 45% for 2014, and Wells Fargo expects that the biotech...
Published:
Last Updated:
24/7 Wall St. wanted to see which analyst picks in mid-cap to large-cap stocks offer the most upside. Some of these stocks still have very big upside targets on the surface.
Published:
One sector that could be poised to do well could be the biotech arena, and the team at RBC has five top stocks for investors to focus on as best ideas.
Published:
24/7 Wall St. has compiled a list health care stocks that Merrill Lynch expects to be top performers in 2015.
Published:
Last Updated:
The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top biotech companies.
Published:
Tuesday's top analyst upgrades and downgrades from 24/7 Wall St. include Cisco Systems, Dreamworks Animation, Lululemon Athletica, Schlumberger and Verizon Communications.
Published:
ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or...
Published:
Last Updated:
ThinkstockIf any sector has had an up and down 2014, it would be the biotech. A massive sell-off in the spring and in the fall has given some biotech investors a serious case of whiplash. However,...
Published:
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.
Published: